3-Indoleacetic Acid-Modified Chondroitin Sulfate-Mediated Paclitaxel Nanocrystal Assembly for the Treatment of Pancreatic Cancer
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.4c19450 ↗At a glance
Journal article in ACS Applied Materials & Interfaces, 2025. Written by Yueting Zhu and 7 co-authors. Institution: Key Laboratory of Drug- Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-S…. Major MEDLINE topics: Pancreatic Neoplasms, Chondroitin Sulfates, Paclitaxel, Nanoparticles. Cited 7 times so far (Crossref); 40 references. Funded by: Science and Technology Department of Sichuan Province, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (original language)
High drug-loading nanocrystals show significant advantages in delivering hydrophobic small-molecule drugs. However, these nanocrystals face challenges, including inherent instability and limited targetability. In this study, we developed a paclitaxel nanocrystal delivery platform based on chondroitin sulfate modified with 3-indoleacetic acid (CS-IAA). Paclitaxel and CS-IAA assembled into stable nanocrystals (PTX@CS-IAA, PC) with a high drug loading (up to 46.6%), facilitated by π-π stacking and hydrophobic interactions. CS-IAA targets tumors through CD44 receptors, which helps to minimize off-target effects. Additionally, CS-IAA, serving as a functional delivery vehicle, can significantly increase reactive oxygen species (ROS) levels at the tumor site. In an orthotopic pancreatic cancer mouse model, PTX@CS-IAA nanocrystals showed significantly enhanced antitumor effects. When PTX@CS-IAA was combined with the αPD-L1 antibody, the survival of mice with pancreatic tumors was further prolonged. This study provides valuable insights into alternative treatment options for pancreatic cancer, with the potential to improve patient prognosis and survival.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Key Laboratory of Drug- Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial…
- Department of Oncology, Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
- School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
ORCID profiles: Tao Gong, Zhirong Zhang, Yao Fu
Funding
- Science and Technology Department of Sichuan Province
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Higher Education Discipline Innovation Project
- MOE Key Laboratory of Drug Targeting and Drug Delivery System
Cite
APA
Zhu, Y., Hu, A., Chen, M., Zhang, Y., Gong, T., Zhang, Z., Yu, R., & Fu, Y. (2025). 3-Indoleacetic Acid-Modified Chondroitin Sulfate-Mediated Paclitaxel Nanocrystal Assembly for the Treatment of Pancreatic Cancer. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c19450
Vancouver
Zhu Y, Hu A, Chen M, Zhang Y, Gong T, Zhang Z, et al. 3-Indoleacetic Acid-Modified Chondroitin Sulfate-Mediated Paclitaxel Nanocrystal Assembly for the Treatment of Pancreatic Cancer. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.4c19450
BibTeX
@article{Zhu2025,
author = {Zhu, Yueting and Hu, Aolei and Chen, Meilin and Zhang, Yunting and Gong, Tao and Zhang, Zhirong and Yu, Ruilian and Fu, Yao},
title = {3-Indoleacetic Acid-Modified Chondroitin Sulfate-Mediated Paclitaxel Nanocrystal Assembly for the Treatment of Pancreatic Cancer},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.4c19450}
}
EUVIMED